Publication at Second Faculty of Medicine |
2010
Abstract
Czech Republic is a country with the highest incidence of kidney cancer. Approximately half of the patients occurs during the development of this disease to metastatic spread, which requires systemic treatment.
Despite the long absence of new drugs over the last five years approved six new active substances. For the first line naïve metastatic cancer is bevacizumab in combination with interferon alfa, sunitinib, sorafenib and pazopanib in patients for whom treatment is not appropriate cytokines, and temsirolimus in high-risk groups of patients.
For the 2nd line therapy is approved sorafenib, sunitinib and pazopanib after failure of cytokine and everolimus after failure of angiogenesis inhibitor therapy.